Earnings ·
Haemonetics Corporation reported first quarter fiscal 2027 financial results for the period ended June 27, 2026
HAEHaemonetics Corp
Haemonetics Corporation reported first quarter fiscal 2027 financial results for the period ended June 27, 2026. Total revenue increased 5.6% to $339.4 million, with organic revenue growth of 5.9%. GAAP diluted earnings per share were $0.72, compared to $0.70 in the prior year period, while adjusted diluted EPS rose 3.6% to $1.14. Operating cash flow improved significantly to $52.3 million from $17.4 million a year earlier, resulting in free cash flow of $39.1 million. The company raised its full-year fiscal 2027 guidance, increasing reported revenue growth expectations to 5-8% and organic revenue growth to 4-7%. Haemonetics Corporation operates in the medical technology industry, providing blood management technologies, apheresis systems, and interventional vascular closure solutions.